T. Rowe Price Associates
RLMD icon

T. Rowe Price Associates’s Relmada Therapeutics RLMD Stock Holding History

T. Rowe Price Associates’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$538K Buy
+77,668
New +$543K ﹤0.01% 2600
2023
Q4 		– Sell
-159,290
Closed -$478K – 2923
2023
Q3 		$478K Sell
159,290
-3,146
-2% -$9.35K ﹤0.01% 2124
2023
Q2 		$400K Sell
162,436
-16,004
-9% -$44.2K ﹤0.01% 2235
2023
Q1 		$404K Sell
178,440
-9,019
-5% -$31.1K ﹤0.01% 2198
2022
Q4 		$654K Sell
187,459
-9,097
-5% -$79.9K ﹤0.01% 2004
2022
Q3 		$7.28M Buy
196,556
+27,799
+16% +$770K ﹤0.01% 1125
2022
Q2 		$3.21M Buy
168,757
+11,192
+7% +$244K ﹤0.01% 1491
2022
Q1 		$4.25M Buy
+157,565
New +$3.26M ﹤0.01% 1493
2021
Q4 		– Sell
-8,057
Closed -$211K – 3031
2021
Q3 		$211K Buy
+8,057
New +$216K ﹤0.01% 2703
2020
Q1 		– Sell
-129,461
Closed -$5.05M – 2551
2019
Q4 		$5.05M Buy
+129,461
New +$3.93M ﹤0.01% 1393

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's RLMD Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 77,668 shares worth $538K. The stake represents ﹤0.01% of the portfolio and ranks #2600 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in RLMD as recently as Q3 2023.

T. Rowe Price Associates first reported a position in RLMD in Q4 2019 and has held it in 10 quarters since. The position peaked at $7.28M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • T. Rowe Price Associates held 77,668 shares of Relmada Therapeutics worth $538K as of Q2 2026.
  • Relmada Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2600 holding.
  • T. Rowe Price Associates first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 10 quarters since.
  • T. Rowe Price Associates's Relmada Therapeutics position peaked at $7.28M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.